Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Impulse Dynamics (Usa), Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Impulse Dynamics (Usa), Inc.

Regulatory records
3
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 3 FDA records to the applicant name Impulse Dynamics (Usa), Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Mar 21, 2019 to Oct 14, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code QFV appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P180036, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 50 Lake Center Executive Pkwy., 401 Rte. 73 N, Bldg. 50 Suite 100, Marlton, NJ, 08053. Recorded on P180036/S046, decision dated Oct 14, 2026.

Changes described in PMA records

P180036/S046: OPTIMIZER Smart and Smart Mini System

FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-14 for P180036/S046, a supplement to the OPTIMIZER Smart and Smart Mini System under applicant Impulse Dynamics (Usa), Inc. The listed supplement reason is a process change involving manufacturer, sterilizer, packager or supplier, and the recorded statement identifies an additional ethylene oxide (EO) sterilizer. The device category is implantable pulse generator, specialty cardiovascular, product code QFV.

This entry documents a manufacturing-process change within the existing P180036 file rather than a new approval of the whole system. The notice does not state which sterilizer facility was added, whether it replaces or supplements existing capacity, or any conditions of the decision. No supporting documents were included in the source record, so the scope of the change and any effect on the cleared system cannot be assessed from this data alone.

The record does not describe clinical, labeling or patient-selection implications, and none should be inferred from the notice.

FDA approval-order wording

an additional ethylene oxide (EO) sterilizer

Oct 14, 2026 · 30-Day Notice

P180036/S044: OPTIMIZER Smart System

The FDA recorded an approval decision on 2026-09-24 for P180036/S044, a PMA supplement to the OPTIMIZER Smart System from Impulse Dynamics (Usa), Inc. The supplement is classified as a Real-Time Process submission with a stated reason of Change Design/Components/Specifications/Material, and the recorded statement describes implementing a new fuse with improved suitability.

This action concerns a component-level change to an implantable pulse generator in the cardiovascular specialty under product code QFV; it is not an approval of the entire system. The source record does not identify the fuse's specifications, the affected device model or the verification performed, and no supporting documents were supplied, so the technical basis for the decision cannot be assessed from this data alone.

FDA approval-order wording

approval for implementing a new fuse with improved suitability

Sep 24, 2026 · Real-Time Process

P180036: OPTIMIZER Smart System

FDA approved the OPTIMIZER Smart System under PMA P180036 on March 21, 2019. The implantable pulse generator delivers Cardiac Contractility Modulation therapy and is indicated to improve 6-minute hall walk distance, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, are not indicated for Cardiac Resynchronization Therapy, and have a left ventricular ejection fraction ranging from 25% to 45%.

The applicant is Impulse Dynamics (Usa), Inc., and the product code is QFV under the cardiovascular specialty. The decision record does not include supplement type or supplement reason fields, so no information is present about whether this entry reflects an original approval or a later change to an existing PMA.

FDA approval-order wording

Approval for the OPTIMIZER Smart System. The device which delivers Cardiac Contractility Modulation therapy, is indicated to improve 6-minute hall walk distance, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, are not indicated for Cardiac Resynchronization Therapy, and have a left ventricular ejection fraction ranging from 25% to 45%.

Mar 21, 2019

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Impulse Dynamics (Usa), Inc.PMA supplementOct 14, 2026FDA
Impulse Dynamics (Usa), Inc.PMA supplementSep 24, 2026FDA
Impulse Dynamics (Usa), Inc.PMA approvalMar 21, 2019FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 19, 2026.